Steve Martin

Virta Advisor and Former CEO of BCBS Nebraska

"Virta's outcomes are unmatched. Health plan leaders should pay attention."

Rapid and sustained Rx cost reduction

Virta’s approach restores metabolic health while actually eliminating the need for expensive prescription medications. No tradeoffs required.

Clinical outcomes that last

Our peer-reviewed research demonstrates transformational health and economic outcomes.

See our research

1.3

HbA1c Reduction¹

Average decrease across all patients, including a 3.5 point reduction for those with A1c ≥ 9

94%

Insulin Reduction¹

% of clinical trial patients who began on insulin and reduced or eliminated dosage at one year

83%

Retention¹

% of patients remaining with Virta after one year. Improves to 90% in commercial population.

Patients are replacing drugs with the Virta treatment. Here's why.

-1.3

-1.8

-1.2

-0.7

-30 lbs

+3.9

-4.4

-$160

$365

$720

$380

$400

Pay for results, not promises

Virta only gets paid if we are successful in delivering real health improvement—the way all payment should work in healthcare.

100% fees at risk for:

A1c Improvements
Weight Loss
Prescription Reductions

We don't charge for:

Implementation
Non-participants
Engagement

Complete your diabetes portfolio by offering reversal

Virta improves your existing diabetes portfolio by providing the choice of reversal for patients who want to eliminate medications while restoring metabolic health. We employ licensed physicians and deliver a high-touch, personalized experience to patients in all 50 states.

Virta easily integrates with your business

Commercial Fully Insured

Deliver a transformational clinical solution
Virta’s physicians complement PCP care, and are licensed to practice in all 50 states
Address high cost pharmacy spend
Deliver transformative outcomes to the 40% of members with diabetes on high cost drugs.
Scale to your full membership
Virta offers the infrastructure of an enterprise-grade vendor and can support massive, nationwide implementations.

40%

Percent of commercial members with diabetes who are on high-cost Rx

Virta quickly and sustainably reduces the need for prescription medications, and can drastically lower Rx claims from members

ASO

Deliver breakthrough outcomes
Employers are blown away by Virta’s clinical and economic impact, with more than 60% of patients achieving reversal
Unlock a new lever for cost savings
Many employers have already tried diabetes management or prevention; reversal is a completely new avenue.
Win and retain more business
Employers agree that Virta represents the next generation of chronic disease management

60%

Percent of ASO patients achieving reversal

More than half of ASO patients who are with Virta for one year achieve diabetes reversal—lowering blood glucose below the diabetes threshold while removing all diabetes-specific medications.

Medicare Advantage

A proven solution for the Medicare population
Virta achieves diabetes reversal rates of 60% within the 65+ population
Tackle diabetes and related co-morbidities
Virta addresses both direct costs of diabetes as well as related risk factors such as cardiovascular health.
Support members who need it most
Diabetes prevalence in Medicare is 2x the rest of the population, and Medicare patients often lack access to specialty diabetes care.

Diabetes prevalence in Medicare population, compared to entire population

Medicare patients are particularly hard-hit by the diabetes epidemic. Virta provides a solution to get Medicare patients healthy—and off of expensive prescription medications.

Concerned about Social Determinants of Health?

Virta delivers high-quality care to the patients who need it most.

Access to transportation

Virta is fully-virtual, available via telemedicine, across the entire U.S.

Access to food

We tailor recommendations to each person’s unique circumstances

Socio-economic status

We built our approach to serve everyone, across socioeconomic strata

Access to community

Patients safely connect with each other within our private community

Citations and Footnotes

Hallberg SJ, McKenzie AL, Williams P, et al. Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at One Year: An Open Label, Non-Randomized, Controlled Study. Diabetes Ther. 2018. DOI: 10.1007/s13300-018-0373-9
Cavaiola TS, Pettus JH. Management Of Type 2 Diabetes: Selecting Amongst Available Pharmacological Agents. [Updated 2017 Mar 31]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK425702/. Numbers selected represent midpoint in range.
Chaudhury A, Duvoor C, Reddy Dendi VS, Kraleti S, Chada A, Ravilla R, Marco A, Shekhawat NS, Montales MT, Kuriakose K, Sasapu A, Beebe A, Patil N, Musham CK, Lohani GP and Mirza W (2017) Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management. Front. Endocrinol. 8:6. doi: 10.3389/fendo.2017.00006. HbA1c estimate represents midpoint of range.
Beverley Balkau, Philip D. Home, Maya Vincent, Michel Marre, Nick Freemantle. Factors Associated With Weight Gain in People With Type 2 Diabetes Starting on Insulin. Diabetes Care Aug 2014, 37 (8) 2108-2113; DOI: 10.2337/dc13-3010